NEW YORK (AP) -- Shares of drug developer Incyte Corp. fell Tuesday after several analysts said that a drug candidate to treat a bone marrow disease has only shown efficacy in treating symptoms of the disease, not the disease itself.
NEW YORK (AP) -- Shares of drug developer Incyte Corp. fell Tuesday after several analysts said that a drug candidate to treat a bone marrow disease has only shown efficacy in treating symptoms of the disease, not the disease itself.
